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Abstract
Background: Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea
form lesions) are therapeutically challenging because they require considerable tissue loss and may
demand radical disfiguring surgery. Interferons (IFN) may provide a non-surgical approach to the
management of these tumors. The aim of this work was to evaluate the effect of a formulation
containing IFNs-α and -γ in synergistic proportions on patients with recurrent, advanced basal cell
(BCC) or squamous cell skin carcinomas (SCSC).
Methods:  Patients with extensive, recurrent, resistant to other procedures BCC or SCSC
received the IFN formulation peri- and intralesionally, three times per week for 3 weeks. They had
been previously treated with surgery and/or radiotherapy or chemotherapy. Thirteen weeks after
the end of treatment, the original lesion sites were examined for histological evidence of remaining
tumor.
Results: Sixteen elder (median 70 years-old) patients were included. They beared 12 BCC and 4
SCSC ranging from 1.5 to 12.5 cm in the longest dimension. At the end of treatment 47% CR
(complete tumor elimination), 40% PR (>30% tumor reduction), and 13% stable disease were
obtained. None of the patients relapsed during the treatment period. The median duration of the
response was 38 months. Only one patient with complete response had relapsed until today.
Principal adverse reactions were influenza-like symptoms well known to occur with interferon
therapy, which were well tolerated.
Conclusion: The peri- and intralesional combination of IFNs-α and -γ was safe and showed effect
for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC
in elder patients. This is the first report of such treatment in patients with advance non-melanoma
skin cancer. The encouraging result justifies further confirmatory trials.
Trial registration: Current Controlled Trials RPCEC00000052.
Published: 30 July 2009
BMC Cancer 2009, 9:262 doi:10.1186/1471-2407-9-262
Received: 3 April 2009
Accepted: 30 July 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/262
© 2009 Anasagasti-Angulo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
Page 2 of 12
(page number not for citation purposes)
Background
Non-melanoma skin cancers (NMSC) have a high inci-
dence over the world, including basal cell carcinoma
(BCC) and squamous cell skin carcinomas (SCSC), the
most common neoplasms of the human being worldwide
[1], irrespective of ethnicity [2]. The incidence of these
tumors has risen [3], probably due to increase of aging
population, improved detection, an increased use of tan-
ning beds, and environmental factors such as increased
sun exposure and ozone layer depletion which are known
to increase the risk of BCC [4]. The role played by the
immune system in immunocompetent patients with skin
cancer is less clear, but ultraviolet (UV) radiation exposure
is recognized as a critical factor in BCC pathogenesis, pre-
sumably partly because of resulting immune suppression
[5]. P53 mutations have been shown in 30 to 50% of
BCCs studied, and more than half of these mutations were
UV-specific. More recently, BCC has bee associated with
increase vascularity likely because of increased expression
of CXCR-4, a receptor for stromal cell-derived factor 1
alpha (SDF-1) [6]. The Glioma-associated oncogene
homolog (Gli) transcription factor family is greatly
expressed in BCC lesions [7], where Hedgehog (Hh) sign-
aling is required for growth of established BCCs [8].
Another way for development of NMSC is to avoid the
immunesurvilance. BCCs have been shown to evade T cell
response by secreting IL-10, by shedding ICAM-1 or by
down-regulation of IFN-γ receptors (and thus HLA-class II
antigens) [9] and by killing infiltrating citotoxic T cells
[10].
Recurrence of BCC is not uncommon, approximately 12%
with most treatment modalities. The rate of recurrence is
positively correlated with tumor size and facial location.
Up to 90% of recurrent cases occur on the head and neck.
Aggressive histological BCC types are more prone to
incomplete excision, recurrence, and metastasis. Tumors
with aggressive histology tend to recur insidiously without
early symptoms, leading to a delay in recognition that
may compound the challenge of management. In a study
of baso-squamous tumors, recurrence predictive factors
included male gender, positive resection margins, and
perineural or lymphatic invasion [11].
Well-known factors that have been shown to promote the
development of SCSC include UV-radiation, immuno-
suppression, exposure to ionizing radiation or chemical
carcinogens, and infection with human papillomavirus
(HPV). Malignant transformation of normal epidermal
keratinocytes is the hallmark of SCSC. One critical patho-
genic event is the development of apoptotic resistance
through functional loss of TP53. Many other genetic
abnormalities are believed to contribute to the pathogen-
esis of SCSC, including mutations of BCL2 and RAS. Like-
wise, alterations in intracellular signal transduction
pathways, including epidermal growth factor receptor
(EGFR) and cyclooxygenase (COX), have been shown to
play a role in the development of SCSC [12].
Medical oncologists owing to success of local therapies
rarely find SCSC. When advanced, SCSC requires systemic
palliation, treatment with conventional chemotherapy,
such as Cisplatin, is often precluded by patient's age or
medical comorbidities [13].
The use of interferons (IFNs) in the treatment of BCC and
SCSC has been reported [14-16], with a broad range of
response (60% – 100%) and low recurrence rate (4%)
[17]. IFN-α has been employed in the treatment of aggres-
sive NMSC with 60% objective response (27% CR + 33%
PR) [18] and 88.2% of complete response (CR) in inva-
sive spinocellular carcinoma with tumor diameter lower
than 2 cm [15].
However, previous report showed IFN as inefficacious in
the treatment of aggressive BCCs, alone or in combination
with retinoid to cure aggressive NMSC [18]. With high
rates of tumor recurrence and with second primary
tumors, patients with aggressive BCC and SCSC continue
to have an unmet medical need, with devastating mortal-
ity, morbidity, and financial consequences [19]. The rising
incidence, morbidity, and mortality of advanced BCC and
SCSC are a major challenge for clinical oncologists. Prom-
ising agents with preclinical and early clinical results rele-
vant to aggressive SCSC deserve a high priority.
Synergistic effects of combined treatment with IFN-α and
-γ have been noted, suggesting that they operate on simi-
lar genes through different mechanisms. The cooperative
induction of cytokine-specific transcription factors is one
mechanism for producing reinforcing effects of distinct
cell-surface ligands while still maintaining the specificities
of the individual inducers [20]. The wide specter of bio-
logical activities shared by both IFNs could contribute to
a more efficacious resolution of this difficult to treat skin
tumors.
We have studied the application of a synergistic formula-
tion of IFNs to explore, as primary objective, the safety
and the clinical response with IFN combination treatment
in advanced, recurrent and non-responder to previous
treatments BCC and SCSC without any other therapeutic




Patients, both genders, older than 18 years, with
advanced, recurrent, without response to previous treat-
ments, not eligible for other available treatments, withBMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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histologically and clinically proven NMSC (BCC or
SCSC), who gave their written informed consent to partic-
ipate were enrolled. Tumors were every subtype, localiza-
tion and size. The study excluded pregnant or nursing
women, patients having at the entry to the study any addi-
tional topical therapy on or around the lesion or systemic
chemotherapy, as well as patients with known hypersen-
sitivity to IFN or with history of autoimmune disease.
After being included, patients were permitted to incorpo-
rate concomitant onco-specific chemotherapy. The trial
protocol was approved by the Ethics Committee and the
Scientific Review Board of the "National Institute of
Oncology and Radiobiology", Havana, in accordance
with the ethical principles stated in the Declaration of
Helsinki. All the patients were recluted and treated in the
medical oncological cabinet (three times per week) suited
in the "National Institute of Oncology and Radiobiol-
ogy".
Trial design
Was conducted a study for the treatment of cases as open
prospective, non-controlled, in only one hospital. The sta-
bilized pharmaceutical formulation of a synergistic com-
bination of IFNs-α and -γ containing 3.0 MIU and sodium
hydrogen-phosphate, dextran 40, sodium chloride, and
human albumin (HeberPAG, Heber Biotec SA, Havana,
Cuba) was employed for the treatment of patients.
This formulation was selected on the basis of in vitro anti-
proliferative studies using isobologram analysis. During
this study were identified the best combinations that lead
to growth inhibition of several tumor cells lines, including
basal cell carcinoma primary cultures from patients with
BCC as well as established cells lines (Hep-2, Laringeal
carcinoma, ATCC:CCL23), HepG2, Hepatoma, ATCC:
HB-8065, and NCI-H125, Non-small cell lung cancer).
Each vial was reconstituted with 1 mL bacteriostatic water
for injection and applied perilesional and/or intralesional
three times per week for 3 weeks. The applications of IFN
combination were practiced by medical doctor specialized
in oncology with 15 years practical experience. For lesions
> 4 cm, tumor area was measured, distributing it as surface
of 1.5 cm2 each. In areas, < 4 cm the product was injected
in equidistant areas. The amount of product to be injected
in 1 mL of total doses (10.0 MIU) per each 1.5 cm2 of
lesion surface was calculated. If the total amount to be
injected was higher than 2 mL, the product was dissolved
in appropriated volume in a sterile flask of approximately
10 mL. Overall, the procedures consumed approximately
no more than 5 minutes.
The employed doses for IFN combination were defined as
3.0, 10.0, or 21.0 MIU based in preclinical and clinical
data and taking in account that doses of IFN higher that
20 millions could produce sever adverse effects [21-23].
Chemotherapy indication
In cases where the tumor infiltrated bone or other cavities
or was far from the needle to be injected, the intralesional
synergistic combination of IFNs application was com-
bined with its intramuscular application and combined
with 1 cycle chemotherapy every 21 days (overall 4
cycles).
The doses and therapeutic schedule of chemotherapy fol-
lowed the established therapeutic guidelines for these
tumors. The chemotherapeutic doses were calculated fol-
lowing the Calver procedure [24]. The indicated cytostatic
drugs were: Cisplatin: 50–100 mg/m2; Carboplatin: 100
mg/m2; Adriamycin: 50–70 mg/m2.
Surgery indication
Surgery were indicated as reconstructive option in one
patient (non therapeutic surgery) and in case of no
response.
Before treatment, each patient had a medical history, a
physical and skin examination for disease assessment,
documentation of concurrent medications, and labora-
tory tests (hemoglobin determination, platelets counts,
white blood cell total, and differential counts). Patients
were asked to avoid any other medication that could inter-
fere with IFN action.
Subjects were examined as outpatients. At each visit dur-
ing and after treatment, the investigators assessed the
lesions and evaluated tissue conditions. Patients' follow-
up examinations were done at weeks 0, 2, 4 and 16 after
treatment onset. At week 16, laboratory tests were
repeated. Lesion diameter (d) measurements were done
using a Folding Magnifier, weekly and at week 16 and doc-
umented with photographs.
Thirteen weeks following therapy, the treatment sites were
examined for clinical and/or histological evidence of
remaining tumor. Patients were followed every 3 months
for 1 one year after conclusion of treatment, and then 2
times a year until today.
Clinical Evaluation
The study will explore if the application of IFN combina-
tion in so difficult to treat tumor is safe and provide ben-
efit to the patients at designed doses.
All cases were examined as outpatients at regular intervals
after injections. The main efficacy evaluation variable was
the lesion response to treatment, based on the lesion area,
13 weeks after the end of treatment. It was categorized asBMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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complete response (CR): total disappearance of the
tumor; partial response (PR): a clearly visible size reduc-
tion (>30%); stable disease (SD): < 30% reduction in the
tumor size; and progression (P) defined as any increase in
the lesion size. The CR responses were confirmed by com-
puterized axial tomography in bone infiltration cases.
Long-term evaluation every 3 months for 1 year included
clinical assessment for local relapses and tumor develop-
ment at other locations. Response rates were based on the
tumor area by measuring the diameter.
Safety evaluation
Safety and tolerability were monitored by means of a rig-
orous adverse events control and their frequency calcu-
lated. During the treatment, patients were carefully
monitored for side effects. Additionally, blood samples
were taken for routine hematological and biochemical
determinations.
Laboratory procedures
Hematological counts and blood chemistry were done
according to usual clinical laboratory procedures, using
advanced automated analyzers. These included hemo-
globin, hematocrit, leukocytes and platelets counts,
transaminases, bilirubin, creatinine and urea. All labora-
tory analyses were done blindly.
Statistic
Data were double entered and validated on Microsoft
Access and then imported into SPSS version 13.0 for anal-
ysis. The frequency distributions for qualitative variables
and central tendency and dispersion were estimated:
mean, standard deviation, median, interquartilic range
(QR), maximum and minimum values (range) for quan-
titative variables.
Effect variables
1. Response: (remission: total, partial, or not remission).
Frequency distribution was estimated (IC 95%) using
Bayesian statistic. The influence of demographic charac-
teristic on clinical response were evaluated.
Safety variables:
2. Adverse events:
For each type of adverse event, were estimated frequency
distribution (IC 95%) with classical and Bayesian statistic.
Overall survival and duration of the response were based
on the Kaplan-Meier method. The influence of demo-
graphic characteristics and appearance of adverse events
were evaluated. The laboratory data were analyzed as a
paired (initial – final result) using paired T student and
Wilkinson tests, depending from Shapiro-Wilk test
results.
Results
Patients demographic and baseline characteristics
The lesions included 12 BCC and 4 SCSC. The clinical
forms were terebrant (9), nodular (3), mixed (2), and
ulcerated (2). The dimension of the tested lesions was
between 1.5 and 12.5 cm. Sites of tumors included face,
neck and trunk.
The study was carried up between 2002 and 2006. Table 1
shows the demographic characteristics of 16 included
patients. Patients were predominantly men (62.5%),
between 31 and 89 years-old. All of them were white.
There was not observed prevalence for smoking (37.5%)
or alcohol consumption (12.5%). Sixth-eight percent of
patients referred concurrent disease, predominantly arte-
rial hypertension and cardiac insufficiency. All patients
had one lesion. Most of recluted patients (93.8%) have
been relapsed under treatments before entry this study,
among them the most frequent were surgery (93.8%) and
radiotherapy (81.2%). The time of tumor evolution was
measured in months. The median of lesion evolution was
36 and 16 months for BCC and SCSC, respectively. The
median of initial tumor area was 19.2 cm2. The main
localization of tumor was in patient face (68.8%) and the
terebrant clinical form was the most frequent (56.3%).
Treatment compliment
Other specific drugs not established in the protocol for
these patients were prohibited. In the study were indi-
cated dipyrone or paracetamol associated to the difenhid-
ramine for the relief of the adverse events. Six patients
maintained during all the treatment time, the specific
drugs for the control of the concurrent illnesses.
The 81.2% of patients completed the treatment schedule
(9 IFN combination injections). Only three patients inter-
rupted the treatment: one because of death, the other
because the product did not penetrate the tumor tissue
and spilled off, and the other by voluntary withdraw. All
of them were included in clinical response analysis. Most
patients received only IFN combination (75%), of them
31.3%, 25% and 43.7% received 3.0 MIU, 10.0 MUI, and
21.0 MIU, respectively. In four patients was necessary to
include chemotherapy to the IFN combination treatment.
The minimum total IFN-α doses received was 30 MIU and
the maximum was 270 MIU. In the case of IFN-γ, the min-
imum total doses received were 4.5 MIU and the maxi-
mum 23 MIU. The most frequent used chemotherapy was
Adriamycin plus Cisplatin. The total doses of Adriamycim
employed were between 120 – 600 mg with a minimum
of 2 cycles and maximum of 5 cycles. In the case of Cispl-BMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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Table 1: Characteristics of the study population at entry
Variable N (16) BCC SSCC Total
Gender Male 7 (58.3%) 3 (75.0%) 10 (62.5%)
Female 5 (41.7%) 1 (25.0%) 6 (37.5%)
Skin color White 16 (100%)
Mean ± SD 66.4 ± 14.1 72 ± 16.3 67.8 ± 14.3
Age (Years) Median ± QR 70.5 ± 18.0 72.5 ± 31.0 70.5 ± 2.0
Max; Min (31, 81) (54, 89) (31, 89)
Smoker Yes 6 (50.0%) 1 (25.0%) 7 (43.5%)
No 6 (50.0%) 3 (75.0%) 9 (56.3%)
Alcohol consumption Yes 1 (8.3%) 1 (25.0%) 2 (12.5%)
No 11 (91.6%) 3 (75%) 14 (87.5%)
No 4 (25%)
Yes 12 (87.5%)









Concurrent diseases (68% of patients) Cardiac insufficiency 4 (25%) Dioxin 1 (25%)
Bronchial asthma 2 (12.5%) Prednisone 1 (50%)
Diabetes 2 (12.5%) Insulin 1 (50%)
Lung ephysema 2 (12.5%) Aminophyline 1 (50%)
Allergic rhinitis 1 (6.2%) Diphenhydramine 1 (100%)
Breast tumor 1 (6.2%)
Duodenal ulcer 1 (6.2%)
Gastric ulcer 1 (6.2%)
Retinosis 1 (6.2%)
Cerebral ischemia 1 (6.2%)BMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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atin the total doses ranged between 195 and 850 mg for a
minimum of 3 cycles and maximums 5 cycles.
Clinical response
Fifteen patients were evaluated for clinical efficacy. Seven
patients obtained CR (46.7%). Six patients had PR
(40.0%). Only two patients were non-responder (13.3%).
Eighty and 83.3% of patients with objective response (CR
+ PR) received 21 MIU and 10.0 MIU IFN combinations,
respectively. In the group of patients that received 3.0 MIU
of IFN combination all the patients obtained overall
response (OR) (1 CR + 3 PR). Surgery was practiced in
three patients after IFN combination treatment. One of
them was a biopsy-exeresis that result in tissue fibrosis,
the other was a surgery indicated as reconstructive option
in one patient (non-therapeutic surgery) and the other in
one case of no response.
It was done univariate analysis of demographic, base and
control variables with respect to the occurrence of CR. In
this case was not observed any significant influence of
analyzed variables with respect to clinical response.
Only one out of 13 patients with clinical OR did not
maintain sustained clinical response until 24 months. The
median of sustained response was 38 months with a con-
fidence interval of 95% (22.6 – 53.4). Five patients (3
SCSC and 2 BCC) dyed in the study (31.3%). The causes
of the death were hepatic metastasis, pneumonia, and
tumor progression. The mean survival was 42.3 months
(95%, 29.4 – 55.2) (see Table 2). Most of the deaths were
before 2 year.
Safety analysis
The exposition time to the IFN combination was between
3 and 18 weeks with a median doses of 166 MIU (30 –
270 MIU) IFN-α and 9 MIU IFN-γ (4.5 MIU – 23 MIU).
Most of the patients (93.3%) developed adverse events.
The most frequent were fever, chills and arthralgias (mod-
erated) (see Table 3). The infrequent (rate = 1) adverse
events were, dyspepsia, plexus brachial pain, otalgia,
increase of aspartate aminotransferase (ASAT), sweating,
nausea, local sepsis, abulia, dyspnea, cardiac arrhythmia,
and ocular pain. Only one severe adverse event was
reported and was related with previous received radiother-
apy. Neither patient abandoned the treatment due to
adverse event.
Discussion
The management of advanced and recurrent NMSC
depends fundamentally from their aggressiveness, magni-
tude of infiltration, tumor size, and/or resistance to stand-
ard treatment, physical state of the patient, etc. The
surgical resolution could be in some case an effective
treatment; nevertheless, in most cases mutilating. The
non-surgical treatment includes the radiotherapy, chemo-
therapy and immunotherapy. On the other hand, patients
with several recurrences and/or resistance to other treat-
ments cannot be tributaries of other therapies.
In the treated cases, BCC was more frequent than SCSC
and located fundamentally in the face. The predominant
clinical form was the terebrant, with median tumors area
of 19.2 cm2 of diameter and some with large extensions
out of the skin [25,26]. The group of IFN combination
treated patients was selected from those previously treated
cases, in relapse after had received insufficient surgical
excision, radiation therapy, or topic chemotherapy. The
risk factors for the subclinic large extension of such
tumors included tumor diameter over 2 cm, localized in
the central part of the face or ears, long evolution time,
incomplete eradication of the tumor, and perineural or
perivascular infiltration. The extensive tumors (> 4 cm) or
irregular edges associated more often with residual posi-
tive margins after surgical excision and have higher rate of
recurrence than the smallest or well defined tumors [27].
Most patients suffered of concurrent cardiovascular or res-
piratory, or digestive illnesses, or diabetes, in concordance
with epidemiological characteristics of Cuban population
at these ages [28]. The concomitant treatment followed by
Table 2: Mortality analysis using Bayes statistics
Variable N (%) IC 95% Bayes
Deaths Yes 5 (31.3) (15.5; 58.6)
No 10 (62.5) (41.0; 84.7)
Unknown 1 (6.2)
Causes of death Hepatic breast carcinoma metastasis 1 (20.0) (4.40; 64.5)
Respiratory infection 2 (40.0) (12.1; 77.6)
Tumor progression 2 (40.0) (12.1; 77.6)
Survival from the beginning of treatment Mean 42.3 ± 6.6 (29.35; 55,21)
Median 56.5 ± 29.4 (0.00; 114.2)BMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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patients apparently did not influence the results obtained
with the IFN combination administration.
Only two patients did not respond to the treatment and
they never received chemotherapy. One of them was a
patient with sclerosant tumor to whom was impossible to
administer the IFN combination. This patient dyed due to
mammary carcinoma lung and liver metastasis, five years
after the failed intent with IFN combination. The other
patient without response suffered from an adenocystic
basal carcinoma, who had received previously radiation
therapy twice, four surgeries, of them two with reconstruc-
tions and long-term topic chemotherapy. In this case, the
tumor was hardened, strongly adhered and with scars that
interfered the drug diffusion. It is known that adenocystic
basal carcinomas are more aggressive and resistant to radi-
otherapy. At this point was decided to carry out a recon-
structive surgery. This patient was not included in the
follow data. Only patients with objective clinical response
were followed for relapses.
With the IFN combination treatment was achieved an OR
in 87% of cases (CR 47% + PR 40%). Most of 12 patients
treated only with IFN combination (84%) obtained an
OR, with completely disappearance of tumor in 50% of
them. The responses in these so difficult to treat cases,
even low or partial or the stabilization deserve the atten-
tion of international community because they are patients
without other treatment options. In the Figures 1, 2, 3,
and 4, are depicted some examples with partial and com-
plete responses.
Patient treatment schedules had some variations due to
differences between treated tumors, mainly in the spread
to other zones or body structures and tumor size. The
incorporation of chemotherapy [29] to the IFN combina-
tion administration showed impressive results in patients,
with OR in 3 evaluated patients (2 CR + 1 PR), large
tumors extended out of the skin and not reached by nee-
dle during the intratumoral IFN administration or with
bone infiltration. In a patient with tumor orbital invasion
the before proposed treatment option was the orbital
Table 3: Adverse events more frequently observed in patients 
treated with the synergistic IFN-α and -γ combination











Palpebral edema 2 1.9
Patient with BCC for more than 30 years treated several  time with surgery and 5-FU and radiation therapies Figure 1
Patient with BCC for more than 30 years treated 
several time with surgery and 5-FU and radiation 
therapies. At the start IFN combination treatment the 
patient had a tumor lesion in free edge of his inferior recon-
structed eyelid. After one-week treatment, it was observed 
in the place of tumor an ulcerated necrotic wound. At the 
end of IFN administration schedule a CR was achieved that 
prolonged for more than 7 years. Other BCC tumor around 
the treated lesion also improved.
        Before treatment           After one-week treatment      After the end of treatment 
Patients with BCC, treated previously with surgery and topic  5-FU with remaining lesion with cartilage infiltration and pain Figure 2
Patients with BCC, treated previously with surgery 
and topic 5-FU with remaining lesion with cartilage 
infiltration and pain. The patient had indicated another 
surgery for resection of the auricular pabellon plus recon-
struction. Upon one week treatment with IFN combination 
pain disappeared and CR was achieved.
Before treatment               After the end of treatment BMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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exenteration, expanded or not [30,31]. The clinical result
obtained for this patient is showed in figure 5 where is
identifiable the organ preservation and functionality
achieved after IFN combination application, verified by
computerized axial tomography. Similar results are infre-
quent in the literature. Those reported were obtained in
patients with less aggressive tumors, of lower size, without
exhausting other therapeutic possibilities or that failed
treatment one time either employing IFN-α along [32,33],
combined with chemotherapy [34,35], or with other pro-
cedures [36,37], all of them with variable outcomes. With
respect to the combination of IFNs-α and -γ has been
reported studies in other types of tumors with variable
responses; mainly with high dose of both IFNs [38-41].
Although the sample of patients that received chemother-
apy combined with IFN combination is small, the results
are impressive and very encouraging. The response is
more prolonged and complete than the employment of
the chemotherapy alone [45,46]. The combination of
IFNs with chemotherapy has been reported to have syner-
gistic effects by sensibilizing cells to apoptosis [42], acting
as immunomodulator [43], potentiating anti-angiogenic
effects [44] and others. This could explain the obtained
and long lasting clinical response of patients treated with
IFN combination plus chemotherapy.
The achieved results have a clear impact because convert
the use of synergistic formulation of IFNs-α and -γ in a
new potent antitumoral treatment to offer to this kind of
patients with sustained long-term response, average of 38
months for the OR (22.6 – 53.4 months). Similar results
have not been reported before employing either chemo-
therapy alone or combined with IFN-α and the obtained
response has not exceeded 12 months average [45-47].
This is the first clinical results using this new stabilized
formulation of synergistic combinations of IFN-α and
IFN-γ (HeberPAG, HeberBiotec, Cuba).
It was reported high percentages of complete sustained
response for five years, during the treatment of invasive
recurrent non-melanoma skin cancer with chemotherapy
Patients with SCSC grade I previously treated with surgery,  topic 5-FU and radiotherapy Figure 3
Patients with SCSC grade I previously treated with 
surgery, topic 5-FU and radiotherapy. He presented an 
extensive tumor lesion in the left ear and external auditory 
conduit and with indication of ear and external auditory con-
duit resection and reconstruction. After IFN combination 
administration a complete clinical response was observed 
that was sustained for 24 months.
 Before treatment                       After the end of treatment  
Patient with BCC induced as consequence of radiotherapy of  SCSC in the area of his left auricular pabellon for more than  10 years of evolution Figure 4
Patient with BCC induced as consequence of radio-
therapy of SCSC in the area of his left auricular 
pabellon for more than 10 years of evolution. The 
patient had indicated to carry out partial temporalectomy 
including pabellon and conduit. He has been treated for three 
times with intralesional IFN combination, and obtained 
always partial or complete response but only for no more 
than 2 months of duration. The intralesional application was 
complemented with intramuscular administration that 
resulted in 85% of clinical response after 9 IFN applications.
Before treatment           After the end of treatment
Serious case of advanced BCC infiltrating and destruction of  both eyelids in left eye, tear region, external wall of nostril  and etmoids cells, constant exit of fetid liquid Figure 5
Serious case of advanced BCC infiltrating and 
destruction of both eyelids in left eye, tear region, 
external wall of nostril and etmoids cells, constant 
exit of fetid liquid. The therapeutic schedule for this 
patient consisted of intralesional administration of IFN com-
bination with concomitant Cisplatin followed by intramuscu-
lar IFN combination. The patient achieved a CR for more 
than 3 years.
Before treatment                                 One year follow-up after treatment  BMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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of the cantus medium and orbit [29] but these cases were
not of the magnitude of reported in our series of cases.
Besides, the literature reports a high percentage of relapses
before 12 months after treatment end. Additionally, the
50% of NMSC that recurred did during the two first years
and 66% during three year, after being treated [48].
Patients, in whom the tumor disappeared after IFN com-
bination treatment, had not yet recurred before 12
months. Even in the case that some one relapsed, it would
be possible to repeat the treatment and to achieve a new
period of diseases stabilization without arriving to major
surgery.
Of five dyed patients; one dyed for causes not relate to
treated tumor (metastasis of concomitant breast cancer);
while in the remainder patients the causes of the death
were related to treated tumor. The causes of death in 4
patients were as followed. Patient-1 dyed of serious hem-
orrhage in artery subclavia related to the tumor; patient-2
of bronchopneumonia by swallowed pus originating
from the tumor tissue infection and perinasal exposed
sinus and tumor cachexia, during tumor progression that
destroyed face and part of the skull, finishing in patient
prostration. Patient-3 death was caused by pneumonia
related to ganglionar metastasis package of cheek and jaw
spinocellular carcinoma that occupied supraclavicular
grave, ulcerated toward the skin of anterior thorax and
mediastine upper third. Patient-4 dyed because of tumor
progression with cachexia and destruction of all centrofa-
cial regions.
After combination treatment with IFNs, three patients
were submitted for surgery. In one of them, upon achiev-
ing CR of more than 18 months (verified with biopsy), a
reconstructive surgery was practiced in the lower eyelid of
affected eye, to improve the ectropion and the functional-
ity of the tear system (Figure 5). The second was to with-
draw from the upper eyelid a small residual nodule of the
extensive original lesion (small basal fibrous carcinoma)
under disappearance by the replacement of tumor by the
fibrous tissue. The third patient did surgery due to no clin-
ical response with IFN combination applications.
The adverse events more frequent reported in the treated
patients were fever (32.7%), chills (12.5%) and artralgia
(10.6%) (see Table 3). Others represented less than 10%
(anorexia, asthenia and diarrheas). The gastrointestinal
related adverse events (anorexia, asthenia, diarrheas,
vomiting, dyspepsia, queasiness) presented in this report
were infrequent with regard to what reports the interna-
tional literature for patients that received interferon (30 –
50%) [49].
Almost all adverse events reported were of low intensity
for which was neither necessary to interrupt any treatment
nor diminish the dose. Only one patient reported pain of
serious intensity in the brachial plexus of affected side
likely as consequence of radiation therapy received. This
patient was maintained under IFN combination treat-
ment with no future complication. This constitutes a very
important fact because frequently due to IFN adverse
events the treatment regimens are interrupted. This toxic-
ity is increased when combines the chemotherpy with
interferon [50,51], a phenomenon that never happened
when combined the chemotherapy with the synergistic
formulation of IFNs-α and -γ.
Almost, all the adverse events evolved in a favorable way
during the treatment course, 51% even without the appli-
cation of any other palliative therapy and 43% with the
prescription of antipyretics. Only 4.6% of them (anorexia,
asthenia and pain in the brachial plexus) persisted in two
patients.
In this study the decrease of leukocytes count to 3 000
during the IFN combination treatment was observed one
time in a single case. ASAT values were increased in a sin-
gle occasion in two patients and never duplicated the val-
ues during the IFN combination treatment.
The adverse events reported in this study are similar to the
described for the IFNs reported in the literature, as for type
of adverse event, intensity and relation of causality, what
indicates us that our synergistic formulation of IFNs pos-
sesses similar therapeutic safety profile as other market
pharmaceutical presentation of IFNs.
The frequency of adverse events and its small magnitude,
as well as the clinical effect of IFN combination, suggest
that this new IFN formulation is harmless and sure, being
able to be employed in similar therapeutic designs and
prolonged treatment schedules, with the aims to offer to
these patients an efficacious and safe therapeutic option.
Possible mechanisms involved in the observed clinical
effects with the combination of IFNs-α and -γ could be the
following. Intralesional IFN-α has been reported to initi-
ate apoptosis of BCC cells via the CD-95 ligand-receptor
interaction, a mechanism that could be reinforced by IFN-
γ through the augmentation of CD-95 receptor [52]. The
IFN-α, stimulating the expression of IFN-γ receptor
(IFNGR1, and IFNGR2) [53] could contribute to reverse
the observed low levels of this membrane receptor in BCC
cells. Additionally it has been demonstrated that the in
the presence of IFN-α, the intracellular signaling of IFN-γ
is stronger [54]. Both IFNs have anti-angiogenic activities
[55,56] and significantly repress CXCR4 gene expression
that can lower the vascularity surrounded NMSC and
impact in SDF-1-induced cell migration and proliferation
of CXCR4-positive cells as have been demonstrated inBMC Cancer 2009, 9:262 http://www.biomedcentral.com/1471-2407/9/262
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head and neck squamous cell carcinomas for IFN-γ [57].
All these properties of IFNs-α and -γ and many others,
likely contribute to enhanced anti-tumoral action of this
new formulation of IFNs.
The prolonged observed clinical response may respond to
the establishment of a more efficient and long-lasting
eradication of tumors by a direct anti-tumor effect, and via
activation of innate and adoptive immune responses
coordinated and stimulated by both IFNs. This may com-
prise dendritic cells activation, tumor antigen presenta-
tion, and T-cell citotoxicity [58]. Such mechanism has
been demonstrated for other treatments with administra-
tion of IFNs [59,60].
According to literature review, no one treatment for BCC
is completely superior and other treatment methods do
offer reliable alternatives. In this context, the treatment of
NMSC with HeberPAG is a valuable option for many
patients suffering from this skin cancer. Never before such
kind of IFN formulation have been used for the treatment
of patients and represents an encouraging therapeutic
option for NMSC.
Conclusion
The results obtained showed the safety and effectiveness
of the synergic formulation of IFNs-α and -γ combination
in the treatment of NMSC of any location, subtype and
size, even in advanced state, and non-responder to previ-
ous therapies. The results of this study permitted to obtain
unique data for IFN combination application in those
non-melanoma skin tumors without any other therapeu-
tic option or with the only option of a mutilating surgery.
The results presented herein establish a candidate new
therapeutic option for these difficult to treat NMSC. Fur-
ther, more extensive, controlled clinical trials are encour-
aged to confirm this assessment.
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